Article
Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma.
Blood - 1 Apr 2021
Li Shirong, Fu Jing, Yang Jun, Ma Huihui, Bhutani Divaya, Mapara Markus Y, Marcireau Christophe, Lentzsch Suzanne
Abstract excerpt
In multiple myeloma (MM), frequent mutations of NRAS, KRAS, or BRAF are found in up to 50% of newly diagnosed patients. The majority of the NRAS, KRAS, and BRAF mutations occur in hotspots causing constitutive activation of the corresponding proteins. Thus, targeting RAS mutation in MM will increase therapeutic efficiency and potentially overcome drug resistance. We identified germinal center kinase (GCK) as a...
Topics
- Animals
- Cell Line, Tumor
- Female
- Gene Expression Regulation, Neoplastic
- Gene Knockdown Techniques
- Gene Silencing
- Genetic Therapy
- Germinal Center Kinases
- Humans
- Mice, SCID
- Molecular Targeted Therapy